156 related articles for article (PubMed ID: 7464555)
1. Plasma lipid concentrations and lecithin:cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol.
Heller FR; Desager JP; Harvengt C
Metabolism; 1981 Jan; 30(1):67-71. PubMed ID: 7464555
[TBL] [Abstract][Full Text] [Related]
2. Plasma lipid concentrations and lecithin: cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol.
Heller F; Desager JP; Harvengt C
Acta Cardiol Suppl; 1981; 27():103-6. PubMed ID: 6977973
[No Abstract] [Full Text] [Related]
3. Low-dose colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia.
Weisweiler P
Metabolism; 1989 Mar; 38(3):271-4. PubMed ID: 2918846
[TBL] [Abstract][Full Text] [Related]
4. Changes in plasma activities of lipolytic enzymes and lipids of normolipidemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate.
Heller FR; Desager JP; Harvengt C
Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):138-42. PubMed ID: 3410596
[TBL] [Abstract][Full Text] [Related]
5. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
Heller F; Harvengt C
Eur J Clin Pharmacol; 1983; 25(1):57-63. PubMed ID: 6617725
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
Weisweiler P; Merk W; Jacob B; Schwandt P
Eur J Clin Pharmacol; 1986; 30(2):191-4. PubMed ID: 3709644
[TBL] [Abstract][Full Text] [Related]
7. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate.
Albers JJ; Chen CH; Adolphson JL
J Lipid Res; 1981 Nov; 22(8):1206-13. PubMed ID: 7320631
[TBL] [Abstract][Full Text] [Related]
8. Lecithin:cholesterol acyl transfer in plasma of normal persons in relation to lipid and lipoprotein concentration.
Wallentin L; Vikrot O
Scand J Clin Lab Invest; 1975 Nov; 35(7):669-76. PubMed ID: 174186
[TBL] [Abstract][Full Text] [Related]
9. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.
Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO
Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197
[TBL] [Abstract][Full Text] [Related]
10. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
Hunninghake DB; Bell C; Olson L
Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
[TBL] [Abstract][Full Text] [Related]
11. Lecithin:cholesterol acyltransferase activity in relation to lipoprotein concentration and lipid composition.
Leiss O; Murawski U; Egge H
Scand J Clin Lab Invest Suppl; 1978; 150():77-84. PubMed ID: 218279
[No Abstract] [Full Text] [Related]
12. Plasma and lipoprotein lipid responses to four hypolipid drugs.
Hazzard WR; Wahl PW; Gagne C; Applebaum-Bowden D; Warnick GR; Albers JJ
Lipids; 1984 Feb; 19(2):73-9. PubMed ID: 6708754
[TBL] [Abstract][Full Text] [Related]
13. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia.
Seplowitz AH; Smith FR; Berns L; Eder HA; Goodman DS
Atherosclerosis; 1981 Apr; 39(1):35-43. PubMed ID: 7018502
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Kłosiewicz-Latoszek L; Szostak WB
Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
[TBL] [Abstract][Full Text] [Related]
17. Structure and biochemical effects of fenofibrate.
Kloer HU
Am J Med; 1987 Nov; 83(5B):3-8. PubMed ID: 3318451
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
19. The effects of colestipol on the metabolism of very-low-density lipoproteins in man.
Witztum JL; Schonfeld G; Weidman SW
J Lab Clin Med; 1976 Dec; 88(6):1008-18. PubMed ID: 186544
[TBL] [Abstract][Full Text] [Related]
20. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
Petit D; Bonnefis MT; Rey C; Infante R
Atherosclerosis; 1988 Dec; 74(3):215-25. PubMed ID: 3240333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
